Imfinzi 50 mg

IMFINZI 50 MG is a solution for intravenous use, containing durvalumab. This medication is used in cancer treatment and is manufactured by AstraZeneca Canada Inc.

IMFINZI 50 MG is primarily used in the treatment of certain types of cancer. Durvalumab, the active ingredient, works by targeting specific proteins involved in cancer cell growth. This medication is often prescribed as part of a broader cancer treatment plan, including what is durvalumab used for in advanced cancer therapies.

Common effects of IMFINZI 50 MG may include fatigue, nausea, and skin reactions at the injection site. Some individuals may also experience appetite loss or shortness of breath. These effects can vary depending on the individual and the specific cancer treatment plan.

IMFINZI 50 MG should be handled with care and administered by healthcare professionals. It is important to follow the prescribed dosage and administration guidelines. Patients should inform their healthcare provider about any existing medical conditions or allergies before starting treatment.

IMFINZI 50 MG may interact with other medications, including those that affect the immune system. It is important to discuss all current medications with a healthcare provider to avoid potential interactions. Alcohol and certain supplements may also affect the efficacy of durvalumab.